M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Electroencephalographic Changes Under General Anesthesia in Patients With Gynecologic Cancers With and Without History of Chemotherapy

Completed

Conditions: Malignant Female Reproductive System Neoplasm

Interventions: Procedure: Biospecimen Collection
Behavioral: BrainCheck Cognitive Assessment
Procedure: Cognitive Assessment
Procedure: Electroencephalography

First Posted Date: 2020-10-20

Last Posted Date: 2023-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT04593550

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Other: Immunotherapy
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2020-10-20

Last Posted Date: 2024-12-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 168

Registration Number: NCT04594187

Locations: 🇺🇸
Baptist - MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸
Cooper Hospital UNIV MED CTR., Camden, New Jersey, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Educating Smokers About Lung Cancer Screening Using Tobacco Quitlines

Not Applicable

Recruiting

Conditions: Lung Carcinoma

Interventions: Other: Educational Intervention
Other: Survey Administration
Other: Questionnaire Administration

First Posted Date: 2020-10-20

Last Posted Date: 2024-10-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 800

Registration Number: NCT04595422

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Financial Toxicity in Cancer Patients

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions: Other: Survey Administration

First Posted Date: 2020-10-19

Last Posted Date: 2024-11-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 625

Registration Number: NCT04592250

Locations: 🇺🇸
DCH Regional Medical Center, Tuscaloosa, Alabama, United States
🇺🇸
Scripps - MD Anderson Cancer Center, La Jolla, California, United States
🇺🇸
Baptist- MD Anderson Cancer Center, Jacksonville, Florida, United States

and more 3 locations

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Phase 1

Recruiting

Conditions: Thyroid Gland Carcinoma

Interventions: Procedure: Magnetic Resonance Imaging
Drug: Hyperpolarized Carbon C 13 Pyruvate

First Posted Date: 2020-10-19

Last Posted Date: 2025-01-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT04589624

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer AJCC v8
Metastatic Prostate Neuroendocrine Carcinoma
Aggressive Variant Prostate Carcinoma
Metastatic Prostate Small Cell Carcinoma

Interventions: Drug: Cabazitaxel
Drug: Carboplatin
Biological: Cetrelimab
Drug: Niraparib

First Posted Date: 2020-10-19

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 120

Registration Number: NCT04592237

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Phase 2

Withdrawn

Conditions: Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Biochemically Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma
Oligometastatic Prostate Carcinoma

Interventions: Drug: Apalutamide
Drug: Degarelix
Drug: Leuprolide Acetate
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2020-10-14

Last Posted Date: 2021-01-20

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04585932

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial

Phase 2

Withdrawn

Conditions: Renal Cell Carcinoma
Stage I Renal Cell Cancer AJCC v8
Stage II Renal Cell Cancer AJCC v8

Interventions: Procedure: Magnetic Resonance Imaging
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2020-10-09

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04580836

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial

Phase 2

Active, not recruiting

Conditions: Stage IIA1 Cervical Cancer FIGO 2018
Stage IIIB Cervical Cancer FIGO 2018
Stage IVA Cervical Cancer FIGO 2018
Stage II Cervical Cancer FIGO 2018
Stage IIIA Cervical Cancer FIGO 2018
Stage IB3 Cervical Cancer FIGO 2018
Stage IIA2 Cervical Cancer FIGO 2018
Stage IIB Cervical Cancer FIGO 2018
Stage III Cervical Cancer FIGO 2018
Stage IIIC2 Cervical Cancer FIGO 2018

Interventions: Drug: Cisplatin
Biological: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
Radiation: Radiation Therapy

First Posted Date: 2020-10-08

Last Posted Date: 2024-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT04580771

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Phase 3

Recruiting

Conditions: Fallopian Tube Endometrioid Tumor
Fallopian Tube Transitional Cell Carcinoma
Ovarian Serous Adenocarcinoma
Primary Peritoneal Transitional Cell Carcinoma
Stage IIIC Fallopian Tube Cancer AJCC v8
Stage IVB Fallopian Tube Cancer AJCC v8
Ovarian Clear Cell Adenocarcinoma
Primary Peritoneal Clear Cell Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Fallopian Tube Serous Neoplasm

Interventions: Drug: Chemotherapy
Procedure: Minimally Invasive Surgery
Procedure: Laparotomy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2020-10-05

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 580

Registration Number: NCT04575935

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸
Duke, Durham, North Carolina, United States
🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy